RhumbLine Advisers
COGT icon

RhumbLine Advisers’s Cogent Biosciences COGT Stock Holding History

RhumbLine Advisers’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.03M Buy
207,609
+32,333
+18% +$1.13M 0.01% 1212
2026
Q1 		$6.75M Sell
175,276
-4,900
-3% -$181K 0.01% 1245
2025
Q4 		$6.4M Buy
180,176
+3,464
+2% +$97.4K 0.01% 1273
2025
Q3 		$2.54M Buy
176,712
+20,195
+13% +$239K ﹤0.01% 1774
2025
Q2 		$1.12M Buy
156,517
+26,059
+20% +$144K ﹤0.01% 2184
2025
Q1 		$781K Buy
130,458
+4,877
+4% +$38.2K ﹤0.01% 2293
2024
Q4 		$980K Buy
125,581
+660
+0.5% +$6.58K ﹤0.01% 2259
2024
Q3 		$1.35M Sell
124,921
-5,595
-4% -$54.5K ﹤0.01% 2107
2024
Q2 		$1.1M Buy
130,516
+11,383
+10% +$86.3K ﹤0.01% 2187
2024
Q1 		$801K Buy
119,133
+3,182
+3% +$19.7K ﹤0.01% 2379
2023
Q4 		$682K Buy
115,951
+2,117
+2% +$16.2K ﹤0.01% 2487
2023
Q3 		$1.11M Buy
113,834
+13,679
+14% +$162K ﹤0.01% 2145
2023
Q2 		$1.19M Buy
100,155
+6,694
+7% +$76.8K ﹤0.01% 2197
2023
Q1 		$1.01M Buy
93,461
+729
+0.8% +$9.32K ﹤0.01% 2114
2022
Q4 		$1.07M Buy
92,732
+3,973
+4% +$49.2K ﹤0.01% 2095
2022
Q3 		$1.32M Buy
88,759
+25,174
+40% +$345K ﹤0.01% 1991
2022
Q2 		$574K Buy
63,585
+22,673
+55% +$155K ﹤0.01% 2423
2022
Q1 		$306K Buy
40,912
+2,057
+5% +$14.3K ﹤0.01% 2641
2021
Q4 		$333K Sell
38,855
-740
-2% -$6.43K ﹤0.01% 2674
2021
Q3 		$333K Buy
39,595
+1,315
+3% +$10.1K ﹤0.01% 2724
2021
Q2 		$310K Buy
+38,280
New +$323K ﹤0.01% 2771
2019
Q2 		– Sell
-4,868
Closed -$85K – 2974
2019
Q1 		$85K Buy
+4,868
New +$83.2K ﹤0.01% 2881

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RhumbLine Advisers's COGT Position: Q2 2026 in Review

RhumbLine Advisers increased its Cogent Biosciences (COGT) stake by 18% in Q2 2026, buying an estimated $1.13M and bringing the position to 207,609 shares worth $8.03M. The position accounts for 0.01% of the portfolio, ranked #1212.

RhumbLine Advisers first reported a position in COGT in Q1 2019 and has held it in 22 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • RhumbLine Advisers held 207,609 shares of Cogent Biosciences worth $8.03M as of Q2 2026.
  • RhumbLine Advisers bought 32,333 Cogent Biosciences shares in Q2 2026, an estimated $1.13M.
  • Cogent Biosciences made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1212 holding.
  • RhumbLine Advisers first reported a position in Cogent Biosciences in Q1 2019 and has held it in 22 quarters since.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.